Contacts:

Kathryn Goldstein
972/581-5529
kgoldste@vha.com

Sean Singh
727/ 388-7326
sean@hemoalliance.org

IRVING, Texas/ Lansdale, Pa (January 14, 2010) – The 340B Prime Vendor Program, managed by Apexus, and the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers in maximizing the benefits of 340B Drug Pricing Program and Prime Vendor Program discounts. The two organizations are working together to assure that covered entities serving the hemophilia community have access to the best possible products and pricing. The collaborative partnership became effective January 1, 2010. “We are excited about this collaboration because it enables us to significantly expand upon the current value the Prime Vendor is delivering to our participants serving the hemophilia community. Hemophilia is a very specialized area and it made sense for both organizations to work together in serving their common customers.” said Chris Hatwig, Vice President of Apexus. Mark Plencner, Chairperson of the Hemophilia Alliance stated “this collaboration gives both organizations the ability to think globally but act locally and keep the focus on delivering outstanding patient care.”

The Hemophilia Alliance

In 1973, the National Hemophilia Foundation launched a campaign to establish the creation of a nationwide network of hemophilia diagnostic and treatment centers. The idea was based upon providing a range of comprehensive services for patients and families within one treatment facility. Today, the Hemophilia Alliance provides member Hemophilia Treatment Centers with resources and services to sustain the Comprehensive Care Model for individuals with bleeding and clotting disorders. The concept of comprehensive care is to treat the whole person and the family, through continuous supervision of all the medical and psychosocial aspects of bleeding disorders. Comprehensive care is total care because every facet of the person is addressed, including their physical, emotional, psychological, educational, financial and vocational factors. The development of comprehensive care over the past 30 years, has greatly improved the quality of life for people with bleeding disorders, helping them to be more independent and productive. The treatment center care network has also lowered patient’s morbidity and provided cost-effective care in the long term. For more information about the Hemophilia Alliance, contact (215) 279-9236 or email at info@hemoalliance.org

The Apexus 340B Prime Vendor Program

The Prime Vendor Program was established to increase the discounts already offered under Section 340B of the U.S. Public Health Service Act, providing low-cost drugs to clinics, hospitals and programs for low-income Americans. Over 13,000 providers across the country qualify to participate in the discount program at no cost, and more than 9,600 facilities are currently enrolled. Apexus Inc., an Irving, Texas-based not-for-profit wholly owned subsidiary of Provista, a group purchasing organization co-owned by VHA Inc. and the University HealthSystem Consortium, administers the program. Visit the Section 340B Prime Vendor Program web site at http://www.340bpvp.com/ for more information about the program.

Click here to read this press release in PDF format.

The next meeting of the Hemophilia Alliance will take place from February 21st to 23rd, 2010 at the Paris Hotel in Las Vegas, Nevada.

• February 21 to 23, 2010
• Room rate $99 per night
• To make your reservation please call the hotel reservations at 1-888-266-5687 and refer to your group code SPHPA0
• Room cut-off is 1/29/10
• This rate is being made available to us one day before and one day after the meeting.

See a PDF of the meeting announcement by clicking here.

The Hemophilia Alliance Foundation announced the culmination of its first grant cycle with the awarding of more than $250,000 to organizations serving people with bleeding disorders. The funding focused on strengthening the effectiveness of the recipient organizations. The goal was to fund one-time project requests and reward collaboration between two or more organizations. The Foundation approved funding for such projects as board development, technology purchases and upgrades, establishment of a regional advocacy group, educational meetings and educational materials.

“The Hemophilia Society of Colorado is proud to receive a 2009 grant from the Hemophilia Alliance. As a Chapter that has been going through some transitional pains, we are greatly appreciative of the support of our Hemophilia Treatment Centers in helping us better meet the needs of our community. We look forward not only to working collaboratively with our local HTC, but also to demonstrating to other Chapters how a functional Chapter should be modeled – one that is truly accountable to the hemophilia community and capable of focusing and delivering on its Mission Statement and long term goals. Such a level of cooperation is essential to improving life for all persons and families dealing with bleeding disorders, now and in the future.” reported Treasurer, Nathan Wilkes.

Joanne Davis, MD, wrote, “At the University of Miami, we are committed to ensuring that our patients and families have complete access to all available educational and financial assistance information. This commitment requires us to make sure that all materials are presented in clear, concise and comprehensible language – both English and Spanish. The 340B program represents a significant savings for eligible families, as well as a source of income to improve and expand HTC services. However, the concept and mechanism of implementation of this program can be confusing! We are very pleased to be able to make our Spanish language 340B materials available to Alliance members, through the support of a grant from the Alliance.”

Robert Fox, President and CEO of the Mary M Gooley Hemophilia Center, wrote “These grants enable people with bleeding disorders to participate in educational offerings, advocacy initiatives and a variety of other programs. The Alliance Foundation is one way that HTCs with factor programs support the communities they serve. In New York, the Alliance Foundation is supporting a statewide effort aimed at giving patients access to elected officials and other decision makers.”

The Foundation also provided $5,000 in funding to each of the 12 federal hemophilia regions in support of their annual meetings. These meetings provide a forum for hemophilia care providers to exchange information and share best practices.

A second grant cycle is planned for early 2010. Leaders of tax-exempt organizations that serve people with bleeding disorders who are interested in more information should contact Joe Pugliese at the Alliance offices 1758 Allentown Road #183 Lansdale, Pa 19446. joe@hemoalliance.org 215-439-7173, or visit our web site.

*The Alliance is a not-for-profit organization that currently comprises 74 Hemophilia Treatment Centers. The
purpose of the Alliance is to assist its members in providing outstanding care for their patients. Our mission
The Hemophilia Alliance provides member Hemophilia Treatment Center with resources and services to
sustain the Comprehensive Care Model for individuals with bleeding and clotting disorders for more
information about the Alliance and how you can help further our mission visit us at www.hemoalliance.org
or email us at info@hemoalliance.org.

FOR IMMEDIATE RELEASE
The Hemophilia Alliance and Definitive Homecare Solutions Announce Strategic Alliance
Industry Leading CPR+ Software to be Made Available to Alliance Members

Lansdale, PA and Columbus, Ohio, August 19, 2009–The Hemophilia Alliance, a non-profit organization serving hemophilia treatment centers nationwide, and Definitive Homecare Solutions, the developer of CPR+ home infusion and specialty pharmacy software, announced today an agreement to offer CPR+ software products to The Hemophilia Alliance’s members at preferred pricing.

“Our mission is to provide member Hemophilia Treatment Center with resources and services to sustain the Comprehensive Care Model for individuals with bleeding and clotting disorders,” said Joe Pugliese, President of The Hemophilia Alliance. “With its leading CPR+ home infusion and specialty pharmacy software, Definitive Homecare Solutions provides a comprehensive business management software solution for specialty pharmacies, with specific functions to meet the unique needs of hemophilia treatment centers. We are pleased to be able to make that solution available to our participating members with preferred pricing.”

The Hemophilia Alliance supports its 73 members with various resources and services, including purchasing benefits for enrolled participating members. Hemophilia treatment centers have specialized pharmacy needs for supplying hemophilia patients with regular infusions of the coagulation factors, usually in their homes, to control the disorder. CPR+ is the leading business management software system for infusion pharmacies, including hemophilia treatment centers.

“We have had the privilege of being the technology partner of many of The Hemophilia Alliance’s members for years and have developed CPR+ to efficiently handle the specific inventory and patient management challenges faced by specialty pharmacies dispensing factor,” said Darren Young, Definitive Homecare Solutions’ Director of Sales. “We are pleased to join with The Hemophilia Alliance in bringing new benefits to our existing Alliance customers, and we look forward to being a partner with all Alliance members.”

Among the patient management challenges facing hemophilia treatment centers is the need to separately track inventories covered under Section 340B of the Public Health Service Act, a federal discount drug program designed to help fund the clinical services provided by covered entities like comprehensive hemophilia treatment centers. The Hemophilia Alliance assists its members with enrolling in the program. Definitive Homecare’s CPR+ software provides users with the ability to separately track these patients and the factor products dispensed to these patients, as required by the program.

The Hemophilia Alliance and Definitive Homecare Solutions will participate in joint marketing efforts to promote CPR+ and the benefits of the program to the Alliance’s participating members.

About Definitive Homecare Solutions
Definitive Homecare Solutions, Ltd. develops and licenses its business and patient management software solution, CPR+ to home infusion, specialty pharmacy, and HME providers. Founded in 1993, Definitive Homecare has grown to be a leading provider of enterprise management software to the homecare industry by providing technology to reduce costs and improve efficiencies in patient management, e-billing, inventory control, and revenue enhancement. With offices in Columbus, Ohio and Irvine, California, Definitive Homecare currently supports more than 850 homecare locations nationwide. For more information, visit http://www.cprplus.com.

About The Hemophilia Alliance
The Alliance is a not-for-profit organization that currently comprises 73 Hemophilia Treatment Centers. The purpose of the Alliance is to assist its members in providing outstanding care for their patients. The Hemophilia Alliance provides member Hemophilia Treatment Centers with resources and services to sustain the Comprehensive Care Model for individuals with bleeding and clotting disorders. For more information, visit http://www.hemoalliance.org.

CSL, a maker of blood-plasma products, said the Federal Trade Commission recommended legal action to block the proposed $3.1 billion purchase of Talecris Bio- therapeutics Holdings.

CSL, which is based in Melbourne, Australia, met with members of the F.T.C. staff in Washington on May 22 to discuss the proposed deal, CSL said on Monday. During that meeting the company was told that the F.T.C. staff members recommended the

commissioners begin legal action in federal court to block the deal, on antitrust grounds, CSL said.

If successful, the takeover would propel CSL to the top spot in the $15 billion global market for medical treatments derived from blood plasma, ahead of Baxter International. The company is trying to capture increasing demand for treatments

for autoimmune diseases like hemophilia and multiple sclerosis.

“A vote and decision by the commissioners is imminent, likely to be announced by May 28 Washington time,” the company said on Monday in a statement to the Australian stock exchange.

Talecris, owned by the private equity groups Cerberus Partners and Ampersand Ventures, had revenue of about $1.4 billion in 2008. CSL had revenue 3.8 billion Australian dollars ($2.97 billion) in the year ended June 2008.